Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Instil Bio, Inc. (NQ: TIL )

26.15 +1.39 (+5.61%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Instil Bio, Inc.

< Previous 1 2 Next >
Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer
From Instil Bio
Via GlobeNewswire
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody
From Instil Bio
Via GlobeNewswire
Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Instil Bio Announces Strategic Update
From Instil Bio
Via GlobeNewswire
Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split
From Instil Bio
Via GlobeNewswire
Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting
Presented novel preclinical data showing that CoStAR enhances activity of CD4+ T cells in multiple ways to broaden anti-tumor response and support CD8+ T cells 
From Instil Bio
Via GlobeNewswire
Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference
From Instil Bio
Via GlobeNewswire
Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
NASDAQ:TIL Shareholder Notice: Investigation over Potential Wrongdoing at Instil Bio, Inc.
San Diego, CA -- (SBWIRE) -- 02/10/2023 -- Certain directors of Instil Bio, Inc. are under investigation over potential breaches of fiduciary duties. 
Via SBWire
Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site
From Instil Bio
Via GlobeNewswire
Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer
From Instil Bio
Via GlobeNewswire
INSTIL BIO ALERT: Bragar Eagel & Squire, P.C. is Investigating Instil Bio, Inc. on Behalf of Instil Bio Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating PROG, Fox, Instil, and Twist and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Newman Ferrara LLP Announces Corporate Governance Investigations of Instil Bio, Inc. (TIL)
From Newman Ferrara LLP
Via Business Wire
Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce
From Instil Bio
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Fox, Instil, Veru, and Twist and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
NASDAQ:TIL Investor Notice: Investigation over Possible Securities Laws Violations by Instil Bio, Inc.
San Diego, CA -- (SBWIRE) -- 11/16/2022 -- An investigation was announced for investors of Instil Bio, Inc. (NASDAQ:TIL) shares over potential securities laws violations by Instil Bio, Inc.. 
Via SBWire
Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Establishment, Accelerate Diagnostics, Instil and Unisys and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Instil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Instil Bio
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Accelerate Diagnostics, and Instil and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INSTIL BIO ALERT: Bragar Eagel & Squire, P.C. is Investigating Instil Bio, Inc. on Behalf of Instil Bio Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Instil Bio, Inc. (TIL) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Instil Bio, Inc. (TIL) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Instil Bio, Inc. (TIL) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.